Changhoon Yoo

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 1K citations · Full text

Medicine, Oncology, Pharmacology +8

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 324 citations · Full text

Medicine, Oncology, Pharmacology +17

Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma

Hyung‐Don Kim, Gi‐Won Song, Seongyeol Park et al. · Gastroenterology · 2018 · 260 citations

Medicine, Immunology, Oncology +16

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Changhoon Yoo, Kyu‐pyo Kim, Jae Ho Jeong et al. · The Lancet Oncology · 2021 · 220 citations

Medicine, Oncology, Pharmacology +14

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo et al. · The Lancet Oncology · 2013 · 186 citations

Medicine, Oncology, Pharmacotherapy +11